PTLA starts phase-1/2 trial of JAK inhibitor for “genetically-defined hematologic cancers”: http://finance.yahoo.com/news/portola-pharmaceuticals-announces-initiation-phase-120000609.html This program is very far town on the valuation totem pole, below Betrixaban and PRT4445.